Fewer than half of adults and youth with type 1 diabetes in the US achieve treatment goals
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, January 22, 2019–A new study has shown that only a minority of patients in the U.S. with type 1 diabetes (T1D) achieve target levels of hemoglobin A1c, a measure of blood glucose management over time. In fact HbA1c levels have increased in young adults and teens in 2016-2018 compared to 2010-2012 according to the study published in Diabetes Technology & Therapeutics (DTT), a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Diabetes Technology & Therapeutics (DTT) website through February 22, 2019.
In the article entitled “State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018,” Nicole Foster and Roy Beck, MD, PhD, Jaeb Center for Health Research (Tampa, FL), and Satish Garg, MD, University of Colorado Denver (Aurora) for the T1D Exchange Clinic, and a team of researchers present the first 5-year study of outcomes from the T1D Exchange registry from the Helmsley Charitable Trust. In addition to reporting on HbA1c levels, the researchers discussed utilization of diabetes technology and various aspects of diabetes management, metabolic control, and acute complication of T1D.
“Despite the availability of newer insulin analogs and increased use of insulin pumps and CGMs in the U.S., the mean A1c levels for patients with type 1 diabetes have increased in the past 5 years and only 1 out 5 patients reach ADA target A1c levels,” says DTT Editor-in-Chief and co-author of the article, Satish Garg, MD, Professor of Medicine and Pediatrics at the University of Colorado Denver (Aurora). “Above all these data represent 30,000 patients followed at the leading centers in the U.S.”
About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, the Journal covers topics that include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the Advanced Technologies & Treatments for Diabetes Conference (ATTD).
The Advanced Technologies & Treatments for Diabetes Conference (ATTD) presents top caliber scientific programs that have provided participants with cutting-edge research and analysis into the latest developments in diabetes-related technology. A unique and innovative conference, ATTD brings the world’s leading researchers and clinicians together for a lively exchange of ideas and information related to the technology, treatment, and prevention of diabetes and related illnesses.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Thyroid, Metabolic Syndrome and Related Disorders, Journal of Aerosol Medicine and Pulmonary Drug Delivery, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Related Journal Article